The majority of asthmatic patients respond well to controller medications, such as inhaled corticosteroids and long-acting β-agonists. However, a subset of patients does not respond to multiple controller medications, including omalizumab, and their asthma symptoms remain poorly controlled. This group of patients is labeled as having refractory asthma (RA) or severe asthma.[@bib1], [@bib2], [@bib3] These patients experience a high level of morbidity because of the disease. Many of these patients require chronic systemic steroid therapy, which results in severe side effects and adds to the morbidity. Because of heavy use of health care services (emergency department and hospital), patients with RA account for a disproportionately higher health care cost.[@bib2] It is estimated that about 3% to 10% of patients have severe RA.[@bib2], [@bib3], [@bib4], [@bib5] The treatment options for RA are limited, primarily because of the lack of understanding of its mechanisms.

Asthma is a heterogeneous disease. Based on clinical and laboratory findings, asthma has been variably classified as atopic versus nonatopic asthma, eosinophilic versus neutrophilic versus noneosinophilic/nonneutrophilic asthma, obesity-associated asthma,[@bib3] asthma/chronic obstructive pulmonary disease overlap syndrome,[@bib6] T~H~2-high asthma,[@bib7] T~H~2/T~H~17-high asthma,[@bib8] and T~H~2-low asthma,[@bib7], [@bib8] for example. Severe asthma and RA can occur within each category of patients. It is unclear whether a single or multiple mechanisms are operating in patients with severe RA. Previous studies have identified a number of factors in patients with severe asthma. Heightened activation of type 1 (T~H~1, the interferon pathway),[@bib9] type 2 (T~H~2 cells, type 2 CD8 T cells),[@bib7], [@bib10] innate response,[@bib11] and airway neutrophilia[@bib12] have all been implicated in patients with RA. Levels of the type 3 cytokines IL-17A and IL-17F are increased in asthmatic patients.[@bib8], [@bib13] However, they were not associated with levels of T~H~17 cytokines in human asthma nor were they associated with neutrophilic asthma,[@bib13], [@bib14], [@bib15] which is unlike what has been reported in the mouse model of asthma.[@bib16] Increased epithelial injury, smooth muscle hyperplasia and hypertrophy, and airway remodeling are some of the recognized intrinsic factors of RA.[@bib1], [@bib2] The external factors associated with RA include heightened exposure to sensitizing allergens,[@bib17], [@bib18] air pollution,[@bib19], [@bib20] and infections.[@bib21], [@bib22], [@bib23] Heightened levels of select cytokines/inflammatory mediators were associated with many of the foregoing subgroups of RA.[@bib23], [@bib24]

Despite progress in the field, there is a need to examine the precise molecular mechanism of heterogeneity of RA that allows development of targeted therapeutic interventions. To address this matter, we studied 60 patients with RA[@bib3] and compared them with 30 patients with nonrefractory asthma (NRA) and 20 healthy control subjects. Bronchoalveolar lavage (BAL) fluid and serum were analyzed for 244 biomolecules, levels of which were then correlated with the clinical and laboratory features of asthma. The latter included pulmonary function, PC~20~ for methacholine, allergic sensitivity, fraction of exhaled nitric oxide (F[eno]{.smallcaps}), body mass index, blood eosinophil counts, total IgE levels, BAL fluid inflammatory cell counts (eosinophil, neutrophil, lymphocyte, and macrophage counts), indices of airway tissue inflammation (quantitative histologic evaluation of bronchial tissue) and basement thickness, and the results of microbiological studies with BAL, tissue biopsy, and airway brushing. The focus of this article is on the neutrophilic phenotype of RA.

Methods {#sec1}
=======

Human subjects {#sec1.1}
--------------

Study subjects with RA were recruited from outpatient clinics of National Jewish Health. Patients with NRA and healthy control subjects were recruited from the community. The study protocol for bronchoscopy and BAL was approved by the institutional review board (HS\#2639). Written informed consent was obtained from the study subjects. Patients were allowed to continue their routine medication. Asthmatic patients had a comprehensive phenotypical and laboratory work-up. The latter included full pulmonary function tests; methacholine tests (if FEV~1~ was \>60% of predicted value); chest computed tomography (CT); F[eno]{.smallcaps} values; blood test results for eosinophils, total IgE levels, and IgE antibody levels (when appropriate); bronchoscopy with BAL; airway brushing; and endobronchial biopsy (see [Fig E1](#figE1){ref-type="fig"}, *A*, in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0010}).

Bronchoscopy, BAL, brushing, biopsy, and other laboratory work-up {#sec1.2}
-----------------------------------------------------------------

The foregoing procedures were performed, as described previously.[@bib25] BAL fluid was processed within an hour. Cells were isolated by means of centrifugation. Supernatant fluid was aliquoted into small samples and frozen at −80°C. Total BAL fluid cells and differential counts; a PCR-based respiratory viral panel (12 different respiratory viruses) with BAL cells and bronchial brushing; a PCR-based test for *Mycoplasma pneumoniae* and *Chlamydophila pneumoniae* with airway biopsy specimens, brushings, and BAL cells; BAL culture in triplicates for bacteria, *Mycobacterium tuberculosis*, and nontuberculous mycobacteria; and a quantitative analysis of airway tissue inflammatory cells, including CD117^+^ mast cells (by using immunohistochemical staining) were performed in the National Jewish Health clinical laboratory (ADx-Advanced Diagnostic Lab, National Jewish Health).

Multiplex biomolecule analyses of BAL fluid and serum {#sec1.3}
-----------------------------------------------------

Aliquots of BAL fluid and serum were analyzed for a total 244 biomolecules (Human Discovery MAP 250+, v2) by Myriad RBM (Austin, Tex). A list of the biomolecules analyzed by using this method is presented in [Table E1](#tblE1){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0015}.

Pathway analyses {#sec1.4}
----------------

We performed pathway analyses for the 36 biomolecules that distinguished RA from NRA. We used multiple software at the [Enrichnet.org](http://Enrichnet.org){#intref0020} Web site: Gene Ontology (GO) for biological process and molecular function, Reactome, and the Kyoto Encyclopedia of Genes and Genomes.

Statistical analyses {#sec1.5}
--------------------

Comparison between study groups was done with the Mann-Whitney *U* test. Comparison among multiple study groups was performed with the Kruskal-Wallis test followed by the Dunn test to correct for multiple comparisons. In addition, we performed the Benjamini-Hochberg test for multiple comparisons, which corrects for false discovery. The false discovery rate for this test was set at 0.1. The Pearson correlation coefficient was used to calculate correlation coefficient. Statistical analyses were performed with Prism software (GraphPad Software, La Jolla, Calif).

Results {#sec2}
=======

Study populations {#sec2.1}
-----------------

We recruited 20 healthy control subjects, 30 patients with well-controlled asthma, and 60 patients with RA, as defined by American Thoracic Society definitions.[@bib26] The patients with NRA did not meet the criteria for RA because their asthma symptoms were well controlled by inhaled corticosteroids and other controllers. Thirty-six percent of patients with RA (22/60) were taking systemic steroids (10-60 mg/d). Asthmatic patients with a history of current or past smoking were excluded from the study. The demographic details of the study population are shown in [Table I](#tbl1){ref-type="table"} .Table IDemographic, clinical, and laboratory features of the study groupsVariableHealthy Control subjects (n = 20)Patients with NRA (n = 30)Patients with RA (n = 60)*P* value, all groups*P* value, NRA vs RAMeanMedianMeanMedianMeanMedianAge (y)33.6 ± 23138 ± 235.554.5 ± 157\<.0001\<.0001Female/male13/719/1136/24BMI (kg/m^2^)29.7 ± 1.229.828 ± 1.127.429.7 ± 0.729.4.12.051Atopy50%66%88%FVC (L)4.1 ± 0.14.33.6 ± 0.13.52.7 ± 0.12.5\<.0001\<.0001FEV~1~ (L)3.3 ± 0.13.42.6 ± 0.12.71.8 ± 0.091.6\<.0001\<.0001FVC (%)101 ± 2.997.592 ± 2.58871 ± 271\<.0001\<.0001FEV~1~ (%)96.5 ± 2.69578 ± 37460 ± 2.555\<.0001\<.0001Reversibility (%)5.2 ± 0.55.517.6 ± 2.11722 ± 2.516\<.0001\<.0001PC~20~ for methacholine25 ± 0252.5 ± 0.5 (n = 29/30)13.4 ± 1.1 (n = 23/60)1.5\<.0001.19F[eno]{.smallcaps}23 ± 32135 ± 328.743.8 ± 622.5.17.55IgE (kU/L)47 ± 933333 ± 199106406 ± 149116\<.001.6Blood eosinophils/μL150 ± 21100283 ± 28300352 ± 43300\<.0001.4Blood PMNs (1000/μL)4.0 ± 0.23.63.6 ± 0.33.26.5 ± 0.45.1.0001.0001BAL WBCs (× 10^6^)10.2 ± 0.89.48.7 ± 0.78.715.8 ± 2.78.6.5BAL eosinophils (% \[total × 10^6^\])0.48 ± 0.1 (0.04 ± 0.01)0.2 (0.022)1.4 ± 0.2 (0.11 ± 0.02)1 (0.079)2.6 ± 0.6 (0.32 ± 0.09)1 (0.042).07 (.19).3 (.6)BAL PMNs (% \[total × 10^6^\])1.9 ± 0.2 (0.19 ± 0.02)1.8 (0.16)2.5 ± 0.4 (0.22 ± 0.05)2 (0.15)10.9 ± 2.4 (3.12 ± 1.8)4.5 (0.40).002 (.003).01 (.004)BAL lymphocytes (% \[total × 10^6^\])6 ± 0.7 (0.61 ± 0.08)5.2 (0.45)6.4 ± 1.1 (0.55 ± 0.12)4.6 (0.30)11.3 ± 1.3 (1.43 ± 0.27)8 (0.60).08 (.2).03 (.1)BAL macrophages (% \[total × 10^6^\])91.5 ± 0.9 (9.42 ± 0.7)92.8 (8.8)89.7 ± 1.2 (7.87 ± 0.6)91.8 (7.6)75.2 ± 2.8 (10.8 ± 1.7)82.5 (6.3).001 (.3).006 (0.7)Biopsy eosinophils/HPF1.2 ± 0.606.1 ± 4.3010.2 ± 3.40.6.4Biopsy PMNs/HPF0.7 ± 0.10.50.4 ± 0.202.3 ± 20.0001.09Biopsy CD117^+^ cells3.8 ± 1.314.9 ± 131.5 ± 0.30.002.001BM thickness6.4 ± 0.667.5 ± 0.67.28.8 ± 0.48.01.04Serum vitamin D28.4 ± 326.437.5 ± 2.634.736.5 ± 2.834.6.056.4[^1]

Clinical and phenotypical characteristics {#sec2.2}
-----------------------------------------

Healthy control subjects and patients with NRA were younger than patients with RA ([Table I](#tbl1){ref-type="table"}). Body mass index was not significantly different among the study groups. Patients with RA were more atopic (88%) than patients with NRA (66%) and healthy control subjects (55%), as judged by skin test positivity or the presence of IgE antibody against an environmental allergen. Pulmonary function indices (forced vital capacity \[FVC\] and FEV~1~) were significantly lower and reversibility was significantly higher in patients with RA compared with those with NRA. There was no difference in PC~20~ for methacholine between patients with RA and those with NRA. F[eno]{.smallcaps} values were not different among the 3 study groups. Blood eosinophil counts and total IgE levels were increased in asthmatic patients (both patients with RA and those with NRA) but were not different between patients with RA and those with NRA. Neither BAL fluid nor airway tissue eosinophil counts showed any significant difference between the NRA and RA groups. In contrast, BAL fluid and airway tissue neutrophil and BAL lymphocyte counts were increased in patients with RA. Surprisingly, numbers of tissue CD117^+^ cells, which mostly represent mast cells, were decreased in patients with RA. Subepithelial basement membrane thickness, a sign of airway remodeling, was significantly increased in asthmatic patients, with the greatest thickness occurring in patients with RA.

Biochemical analyses of BAL fluid {#sec2.3}
---------------------------------

Of the 244 biomolecules assayed with the Human DiscoveryMAPs v2 multiplex assay, 66 were less than the detection limit (see [Fig E1](#figE1){ref-type="fig"}, *B*). One hundred one biomolecules did not show any significant difference among the study groups: healthy control subjects, patients with NRA, and patients with RA. Fifty-two biomolecules were significantly different either in multigroup comparisons or in comparisons between patients with RA and those with NRA ([Table II](#tbl2){ref-type="table"} ). Thirty-seven of these 52 biomolecules distinguished patients with RA from those with NRA ([Table II](#tbl2){ref-type="table"} and see [Fig E1](#figE1){ref-type="fig"}, *C*). Because BAL fluid neutrophils were one of the cell types that distinguished patients with RA from those with NRA, we focused on neutrophil-associated biomolecules for this study. We identified 17 neutrophil-associated biomolecules with levels that were significantly increased in patients with RA when compared with those in patients with NRA and healthy control subjects ([Table III](#tbl3){ref-type="table"} ). Of these 17 biomolecules, 13 showed a significant positive correlation with the BAL fluid neutrophil count ([Table IV](#tbl4){ref-type="table"} ). Four biomolecules did not show any significant correlation. It is noteworthy that levels of only one of these 13 biomolecules, CCL3 (macrophage inflammatory protein 1β), correlated with BAL fluid eosinophil counts. We classified these biomolecules based on their published cellular sources (see [Table E2](#tblE2){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0025}). This classification suggests that innate immune and airway tissue cells are the primary source of RA-associated proneutrophilic biomolecules. This also implies that activation of innate immune and airway tissue cells contributes significantly to RA.Table IIBiomolecules that are statistically different among the study groupsBiomoleculesHealthy subjects (n = 20)Patients with NRA (n = 40)*P* value vs healthy subjectsPatients with RA (n = 60)*P* value vs healthy subjects*P* value vs NRA*P* value for multigroup analyses1. α-1 Antitrypsin[∗](#tbl2fnlowast){ref-type="table-fn"} (μg/mL)0.40.7NS1.5.009.01.0052. Angiogenin (ng/mL)0.630.6NS0.85.002.003.0073. Apolipoprotein C III (μg/mL)0.010.018NS0.027.02NSNS4. Apolipoprotein E (ng/mL)0.10.95.0081.5.001NS.0015. Axl receptor (ng/mL)1.20.6\<.0010.39.001NS.0046. C3 (ng/mL)0.340.33NS0.66.04.03.037. CCL3 (MIP1β) (pg/mL)1112NS23.007.002.00018. CCL5 (RANTES \[pg/mL\])6.87.2NS12.009.03.019. CCL20 (MIP3α \[pg/mL\])1916NS31NS.02NS10. CCL21 (pg/mL)3.84NS5.1NS.01.0211. CXCL9 (MIG \[pg/mL\])6979NS138NS.02NS12. EGF (pg/mL)1.11.3NS2.6NS.01.0313. Ferritin (ng/mL)6.15.5NS9.8.01.03.0114. Ficolin 3 (ng/mL)8.26.5NS11.03.001.00215. Human epididymis protein 4 (pmol/L)50003820NS4980NS.01.0316. IL-1β (pg/mL)00NS0.07.01.0117. IL-6 (pg/mL)00.010NS.005.00318. IL-8 (pg/mL)1111NS24.01.002.000519. IL-18 (pg/mL)12034.0314.007.003.00120. IL-22 (pg/mL)170100.00159\<.001.001\<.00121. Kallikrein 7 (pg/mL)00NS145NS.006.00222. Lipocalin 2 (ng/mL)6582NS111.05.04.0423. MIF (pg/mL)0.391.5.00071.3.0016NS.00424. MMP3 (ng/mL)00NS0.01\<.001\<.001\<.00125. MMP7 (ng/mL)0.90.6.0011.4NS.04.0426. MMP9, total (ng/mL)2.94.3NS20\<.001\<.001\<.00127. Myeloperoxidase (ng/mL)5146NS133.0002\<.0001\<.000128. Myoglobin (ng/mL)0.570.94.030.91.04NSNS29. NAP2 (pg/mL)0.410.79NS1.7.01.02.00130. Neuropilin 1 (pg/mL)980560.001580\<.001NS.00131. Osteoprotegerin (pmol/L)00NS0NS.006.0232. PAI-1 (pg/mL)4241NS11\<.001\<.001\<.00133. Pepsinogen I (ng/mL)0.0640.06NS0.093.007\<.001.00134. Pigment epithelium-derived factor (ng/mL)3.26.3NS11.02.006.00535. Progranulin (ng/mL)135.2.014.03NS.00736. Prostasin (ng/mL)520309.01278.001NS.00537. RAGE0.31NS6.5\<.001\<.001\<.00138. Soluble CD25 (pg/mL)6939NS29.003.01.00139. Soluble CD40 (ng/mL)0.0930.056.0080.05.002NS.0340. SAA (ng/mL)0.510.57NS2.0002.001.00341. Soluble ICAM (pg/mL)3019.0416.004NS.0242. Soluble IL-1 receptor (pg/mL)6526.0122.003NS.00843. Sortilin (ng/mL)00.05NS0.12.01.01.00844. SP-D[∗](#tbl2fnlowast){ref-type="table-fn"} (ng/mL)5039NS35.5.01NS.0445. Thrombospondin 1 (ng/mL)01.4NS4.4\<.001\<.001\<.00146. TIMP-1 (ng/mL)1.31.8NS3.1.004.003.00147. TNFSF12 (pg/mL)5030NS20.006.01.00148. TNFSF13 (pg/mL)184.3.0021.3.001NS.00149. Trefoil factor 3 (μg/mL)0.10.22NS0.42.004.004.00650. VEGF (pg/mL)364292NS177.001NS.00851. Vitamin D binding protein[∗](#tbl2fnlowast){ref-type="table-fn"} (μg/mL)0.340.15.0020.2.01NS.00852. vWF (μg/mL)0.0040.008NS0.012.003.002.009[^2][^3]Table IIINeutrophil-associated biomolecules that are statistically different among the study groupsBiomoleculesHealthy subjects (n = 20)Patients with NRA (n = 40)*P* value vs healthy subjectsPatients with RA (n = 60)*P* value vs healthy subjects*P* value vs NRA*P* value for multigroup analyses1. C3 (ng/mL)0.340.33NS0.66.06.03.032. CCL3 (MIP1β \[pg/mL\])1112NS23.007.002.00013. CCL20 (MIP3α \[pg/mL\])1916NS31NS.02.054. EGF (pg/mL)1.11.3NS2.6NS.01.035. Ficolin 3 (ng/mL)8.26.5NS11.03.001.0026. IL-1β (pg/mL)00NS0.07.01.017. IL-6 (pg/mL)00.010NS.005.0038. IL-8 (pg/mL)1111NS24.01.002.00059. Lipocalin 2 (ng/mL)6582NS111.05.04.0410. MMP7 (ng/mL)0.680.6NS1.6.002.0003.000311. MMP9, total (ng/mL)2.94.3NS20\<.001\<.001\<.00112. Myeloperoxidase (ng/mL)5146NS133.0002\<.0001\<.000113. NAP2 (pg/mL)0.410.79NS1.7.01.02.00114. RAGE0.31NS6.5\<.001\<.001\<.00115. SAA (ng/mL)0.510.57NS2.0002.001.00316. Thrombospondin 1 (ng/mL)01.4NS4.4\<.001\<.001\<.00117. TIMP-1 (ng/mL)1.31.8NS3.1.004.003.001[^4]Table IVCorrelation of BAL fluid biomolecule level with inflammatory and other biological processesBiomoleculesCorrelation with BAL fluid neutrophils *(r)P* valueCorrelation with BAL fluid eosinophils *(r)P* valueCorrelation with BAL fluid lymphocytes *(r)P* valueGroup 1. Biomolecules correlated with neutrophils 1. Lipocalin 20.86\<.0010.13NS−0.15NS 2. SAA0.70\<.0010.25NS0.002NS 3. CXCL7 (NAP2)0.65\<.0010.07NS0.002NS 4. IL-80.62\<.001−0.04NS0.06NS *5. Thrombospondin 1*0.60\<.0010.06NS0.15NS 6. IL-1β0.58\<.0010.05NS0.03NS *7. Ficolin 3*0.57.0010.18NS0.32.03 8. IL-60.52\<.0010.07NS0.17NS 9. PAI0.46.003−0.02NS−0.02NS 10. MMP70.41.010.12NS0.16NS 11. MMP9, total0.37.0030.05NS−0.07NSGroup 2. Biomolecules correlated with multiple inflammatory cells 1. C30.48\<.0010.11NS0.45.002 2. CCL3 (MIP1β)0.36.0060.41.0010.19NSGroup 3. Known proneutrophilic biomolecules not correlated with neutrophils 1. CCL200.12NS0.09NS0.05NS 2. EGF−0.01NS0.13NS0.01NS 3. RAGE−0.01NS0.13NS0.08NS 4. TIMP-10.21NS0.23NS0.36NS[^5][^6]

Biochemical analyses of serum {#sec2.4}
-----------------------------

Of the 244 biomolecules assayed, 29 were undetectable. One hundred seventy-two biomolecules did not show any difference among the study groups. Fourteen biomolecules were significantly different among all 3 study groups and also between patients with NRA and those with RA ([Table V](#tbl5){ref-type="table"} ). Of these 14 biomolecules, 6 of them were also detected in BAL fluid and were different among the study groups. They include ficolin 3, matrix metalloproteinase (MMP) 7, thrombospondin 1, apolipoprotein E, human epididymis protein 4, and neuropilin 1.Table VSerum biomolecules with levels that are statistically different among the study groupsBiomolecules (total n = 14)Healthy subjects (n = 20)Patients with NRA (n = 40)*P* values vs healthy subjectsPatients with RA (n = 60)*P* values vs healthy subjects*P* value vs NRA*P* values for multigroup analysesProinflammatory 1. CCL18 (PARC \[ng/mL\])10597NS146.006.0006.0006 2. Cathepsin D569480.02585NS\<.0001.004 *3. Ficolin 3* (μg/mL)21.521NS29NS.002.002 4. GDF-15 (ng/mL)0.330.32NS0.40NS.02.03 5. Thrombin-activatable fibrinolysis (μg/mL)11.88.6.00811NS.005.005 6. von Willebrand factor (μg/mL)109.561.08120NS\<.0001.0002 7. YKL-40 (ng/mL)4027NS42NS.003.008Remodeling/regeneration/angiogenesis *1. MMP7* (ng/mL)5.74.1.035.1NS.002.009 2. Tenascin C (ng/mL)493400NS733.009.003.002 3. Tetranectin (μg/mL)2220NS18.002.02.005 *4. Thrombospondin 1* (μg/mL)14.712.0114NS.001.004Anti-inflammatory *1. Apolipoprotein E* (ng/mL)6556NS65NS.01.07 *2. Human epididymis protein 4* (pmol/L)690555.07787NS.002.005 *3. Neuropilin 1* (pg/mL)248177.005214.003.006.003[^7][^8]

Next, we examined the correlation of these serum biomolecules with BAL fluid inflammatory cells (see [Table E3](#tblE3){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0030}). Five biomolecules correlated with increased BAL fluid neutrophils: growth and differentiation factor 15 (GDF-15), human epididymis protein 4, MMP7, tetranectin, and von Willebrand factor. None of these biomolecules correlated with BAL fluid eosinophil or lymphocyte counts.

Microbial analyses of BAL fluid {#sec2.5}
-------------------------------

BAL fluid from each patient was cultured in triplicate to detect pathogenic microbial organisms. The results were presented as negative or normal respiratory flora or positive for a pathogenic strain. A total of 24 of 60 patients with RA had positive results for bacteria, a virus, or both. The following bacterial strains were identified in 22 patients with RA: methicillin-sensitive *Staphylococcus aureus* (7 patients), methicillin-resistant *Staphylococcus aureus* (1 patient), *Pseudomonas aeruginosa* (5 patients), *Haemophilus influenzae* (1 patient), *Haemophilus* species but not *influenzae* (subspecies not identified, 2 patients), *Haemophilus parainfluenzae* (1 patient), β-hemolytic Streptococci (not group A) (1 patient), α-hemolytic streptococci (1 patient), *Streptococcus pneumoniae* (1 patient), *Moraxella catarrhalis* (1 patient), *Serratia marcescens* (1 patient), and *Capnacytophaga* species (1 patient). Note that some patients had more than 1 strain of bacteria. Two patients had positive result for viruses only (1 with respiratory syncytial virus and 1 with coronavirus OC43). Four patients with a bacterial isolate also had positive results for viruses (3 with rhinovirus and 1 with parainfluenza virus 3). It should be noted that these infections were subclinical in nature because the patients did not report symptoms of acute infection (fever, coryza, pharyngitis, or myalgia). All patients had chest CT. A summary of chest CT findings from patients with positive results for infection is shown in [Table E4](#tblE4){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0035}. One patient with *Pseudomonas* species had consolidation; 1 patient with *Serratia marcescens* had infiltrates, and 3 patients had ground-glass opacity. The rest of the patients did not have any sign of acute infection.

Effect of infection on clinical and laboratory parameters of RA {#sec2.6}
---------------------------------------------------------------

Next, we examined the effect of infection on cellular and molecular parameters in patients with RA. As anticipated, infection increased the frequency of neutrophils more than that of eosinophils in the airways when compared with that seen in patients with NRA (see [Fig E1](#figE1){ref-type="fig"}, *B*). This was associated with a dramatic increase in levels of the neutrophilic granular protein myeloperoxidase (see [Fig E1](#figE1){ref-type="fig"}, *A*) and a number of proneutrophilic biomolecules, especially MMP9, thrombospondin 1, IL-8, IL-1β, serum amyloid A (SAA), IL-6, lipocalin 2, neutrophil activating peptide-2 (NAP2), and 6 conserved cysteine containing CC-chemokine (see [Fig E1](#figE1){ref-type="fig"}, *B*). Although the foregoing changes were statistically significant for the groups, not all infection-positive patients with RA had increased BAL fluid neutrophil counts. Of the 24 infection-positive patients with RA, 15 had increased neutrophil frequencies (≥3%, threshold based on the normal range for the clinical laboratory) in BAL fluid, and 9 did not. Ten of these 15 infection-positive neutrophilic asthmatic patients had increased (≥1%) eosinophil frequencies in BAL fluid. Conversely, 4 of the 9 infection-positive but nonneutrophilic patients had increased eosinophil counts in BAL fluid.

We compared BAL fluid neutrophil frequencies (as a percentage) and absolute neutrophil counts in blood among infection-positive and infection-negative patients with RA and those with NRA. A total of 22 patients with RA (10 with infection-positive RA and 12 with infection-negative RA) were receiving systemic steroids, which could have a direct effect on blood and BAL fluid neutrophil counts. For this reason, we analyzed data with and without inclusion of patients receiving oral corticosteroids (OCSs). BAL fluid neutrophil counts were increased in both infection-positive and infection-negative patients with RA regardless of their OCS use compared with healthy control subjects ([Fig 1](#fig1){ref-type="fig"} , *A*). Blood neutrophil counts were also increased in both infection-positive and infection-negative patients with RA when the data were analyzed for the entire group ([Fig 1](#fig1){ref-type="fig"}, *B*). However, this increase was lost in the blood but not BAL fluid ([Fig 1](#fig1){ref-type="fig"}, *C* and *D*) in the infection-negative RA group when the patients receiving OCSs were excluded from analysis. The results suggest that blood neutrophilia in infection-negative patients with RA was caused by OCSs. Strikingly, the absolute neutrophil number remained increased in the infection-positive RA group, even when the patients receiving OCSs were excluded from the analysis. The results indicate that an increase in absolute neutrophil counts could serve as a blood biomarker for airway infection in patients with RA. The results also suggest that blood neutrophilia in this subgroup was due to airway infection ([Fig 1](#fig1){ref-type="fig"}, *C*).Fig 1**A-D,** Comparison of blood and BAL fluid neutrophil counts among infection-positive *(Inf+)* and infection-negative *(Inf−)* patients with RA and patients with NRA, including and excluding patients with RA taking OCSs.

Asthma is a type 2 immune response disease, and eosinophils play an important role. As noted earlier, the median BAL fluid eosinophil number did not increase significantly in patients with RA compared with those with NRA. Because infection contributed to RA in a significant number of patients, we reasoned that the former might have affected the eosinophilic influx by favoring neutrophilic influx. For this reason, we analyzed BAL fluid eosinophils and neutrophils separately in infection-positive and infection-negative patients with RA and compared them with counts in patients with NRA. Median BAL eosinophil counts were 1, 1, and 1 in patients with NRA, infection-positive patients with RA, and patients with infection-negative RA, respectively. On the other hand, median BAL fluid neutrophil counts were 2.2, 8, and 3.2 in patients with NRA, infection-positive patients with RA, and infection-negative patients with RA, respectively, and the difference among the groups was statistically significant (*P* = .02).

Serum biomolecules that identify neutrophilic asthma in noninfected patients {#sec2.7}
----------------------------------------------------------------------------

Subclinical infection was the most plausible explanation for increased airway neutrophil counts in our infection-positive patients with RA. The cause of neutrophilic asthma in infection-negative patients with RA was of major interest to us. To this goal, we compared serum proneutrophilic biomolecule levels between infection-negative and infection-positive patients with RA ([Fig 2](#fig2){ref-type="fig"} ). IL-1β, IL-6, IL-8, CXCL1, and CCL3 levels were increased in serum from infection-negative patients with RA compared with those in infection-positive patients with RA and NRA. Interestingly, the BAL fluid concentrations of these molecules were not increased in the infection-negative patients with RA when compared with those in infection-positive patients with RA. The results raised the possibility of a systemic inflammatory process contributing to airway neutrophilia in infection-negative patients with RA.Fig 2Comparison of biomolecule levels between serum and BAL fluid among infection-positive *(Inf+)* patients with RA, infection-negative *(Inf−)* patients with RA, and patients with NRA.

Next, we compared levels of C-reactive protein, soluble ST2 (serum stimulation 2, also known as suppressor of tumorigenicity 2), and GDF-15, 3 molecules associated with atherosclerosis, cardiovascular diseases, and systemic inflammatory diseases.[@bib27], [@bib28] Indeed, levels of all 3 molecules were increased in infection-negative but not infection-positive patients with neutrophilic asthma ([Fig 3](#fig3){ref-type="fig"} ). The erythrocyte sedimentation rate was similar in both groups. We were concerned about a potential role for inhaled corticosteroids in airway neutrophilia. To this goal, we compared inhaled corticosteroid treatment of patients with NRA and those with RA (see [Table E5](#tblE5){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0040}). All patients with RA were receiving high-dose inhaled steroids and long-acting β-agonists. In contrast, some patients with NRA were receiving low- to medium-dose inhaled steroids. Thus it is possible that this difference in the dose of inhaled steroids contributed to airway neutrophilia.Fig 3Comparison of systemic inflammatory markers in serum from infection-positive *(Inf+)* patients with RA, infection-negative *(Inf−)* patients with RA, and patients with NRA.

Clinical correlations {#sec2.8}
---------------------

Next, we examined the clinical correlation of airway inflammatory cells and biomolecules. There was a positive correlation (*r* = 0.49, *P* \< .001) between the age of the patient and the BAL PMN count. Age also positively correlated with FVC (*r* = 0.52, *P* \< .05) and BAL fluid IL-1β levels (*r* = 0.67, *P* \< .001) but not with levels of other proneutrophilic biomolecules, including IL-6 (*r* = 0.40) and IL-8 (*r* = 0.18). BAL fluid PMN counts but not BAL fluid eosinophil, lymphocyte, or blood eosinophil counts negatively correlated with FVC percentages (see [Table E6](#tblE6){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0045}). CD117^+^ cells, which largely but not exclusively represent mast cells, did not correlate with levels of any BAL biomolecules. Levels of 2 BAL fluid biomolecules correlated with 2 pulmonary function indices. Myoglobin levels negatively correlated with FVC percentage, whereas prostasin levels negatively correlated with reversibility and positively with FEV~1~ percentage. We performed pathway analyses with the 36 BAL fluid biomolecules that distinguished patients with RA from those with NRA. We compared pathway results by using GO for biological process and molecular function, Reactome, and Kyoto Encyclopedia of Genes and Genomes (data not shown). The GO analysis identified the most meaningful pathways. The top pathways included neutrophil chemotaxis, chemokine receptor signaling, fibroblast growth factor stimulation, and cellular response to IL-1 (see [Table E7](#tblE7){ref-type="table"} in this article\'s Online Repository at [www.jacionline.org](http://www.jacionline.org){#intref0050}).

Discussion {#sec3}
==========

We showed that RA was associated with an increase in neutrophil and lymphocyte counts in the airways. As mentioned previously, we specifically focused on neutrophilic asthma in this article. There was a concurrent increase in levels of a multitude of biomolecules known to be associated with innate immune and airway tissue responses. We identified 51 biomolecules with increased levels in asthmatic patients, and 36 of them distinguished RA from NRA. Sixteen biomolecules correlated with neutrophilic asthma. The vast majority of these biomolecules are known to be produced by macrophages and airway epithelial cells, which indirectly points to their role in patients with neutrophilic asthma. A pathway analysis identified neutrophilic influx as an important biological process in RA. Multiple previous studies demonstrated a similar role for neutrophilic inflammation in severe asthma. Our RA group resembles cluster 5 (neutrophilic) of the SARP cohort.[@bib29] In a subsequent study of SARP patients, increased neutrophil and mixed neutrophil and eosinophil counts in the sputum (clusters C and D) were associated with asthma severity.[@bib30] Our patients with RA are similar to those of cluster H (mixed neutrophilic/eosinophilic) of the multinational study by Hinks et al.[@bib31] This cluster had severe asthma, which was associated with increased IL-6, IL-8, MMP3, and MMP8 levels in sputum.

One of the weaknesses of this study is that patients with RA were significantly older than patients with NRA. RA is more prevalent in older patients,[@bib4], [@bib5] which led to this unintended recruitment outcome. Increased age is associated with sputum neutrophilia, even in nonasthmatic subjects.[@bib32] Thus increased age could affect the quality and quantity of the mediators involved in neutrophilic asthma.

We used a commercially available multiplex assay service for measurement of biomolecules. Multiplex assays are less sensitive than other highly sensitive assays (eg, ELISA). This perhaps explains why we did not detect the typical type 2 (eg, IL-4, IL-5, and IL-13) or type 3 (IL-17) cytokines. However, the scope of biomolecules detected by using this assay is an advantage.

One outstanding issue related to the heightened production of proneutrophilic biomolecules is what induces their production in patients with RA. We observed subclinical infection (both bacterial and viral) in one third of the patients with RA. This subclinical infection could stimulate production of proneutrophilic biomolecules. We used standard microbiological cultures to detect bacteria. The sensitivity of these cultures is relatively low when compared with that of DNA-based technologies. It is possible that new technologies will identify additional patients with subclinical infections, which could explain increased airway neutrophil counts in the currently classified infection-negative patients.

The persistence of infection at a subclinical level in a subgroup of patients raises concerns for a defective immune response. This inability to clear infection could be primary or secondary to ongoing treatment with steroids (inhaled steroids in all patients and systemic steroids in 36% of patients with RA). The potential role of inhaled steroids in patients with subclinical infection cannot be addressed at this time because their discontinuation in patients with RA will be considered unethical.

We detected decreased IL-18 and IL-22 levels in patients with RA. Low IL-18 levels were previously reported in sputum from asthmatic patients and in patients during rhinovirus infection.[@bib33], [@bib34] IL-18 and IL-22 are important for defense against infection.[@bib35], [@bib36] Their decrease could impair clearance of infection. Macrophage scavenging of infected and dead cells is important for resolution of inflammation.

Axl receptor tyrosine kinase is specifically expressed on airway macrophages.[@bib37] We observed decreased expression of Axl receptor in BAL, which suggested a decreased expression on macrophages and, consequently, an impaired scavenger function. The latter could promote persistence of infection.

Thrombospondin 1 is a multifunctional and pleiotropic protein, levels of which are increased in patients with RA. It was recently reported to inhibit bactericidal activity of neutrophils and delay the clearance of lung infection.[@bib38] Thus we have identified a number of biomolecules that could promote persistence of subclinical infection in patients with RA.

Systemic glucocorticoids are known to induce blood and tissue neutrophilia.[@bib39] Thirty-six percent of patients with RA were taking systemic steroids. Our analysis of patients who were not taking OCSs suggested that systemic steroids contributed to blood but not airway neutrophilia in infection-negative patients with RA. Our understanding of the role of inhaled steroids in patients with airway neutrophilia is incomplete. A previous study showed that systemic but not inhaled steroids were associated with tissue neutrophilia.[@bib39] However, this study was done with a small number of patients, and the result showed a trend for increased airway neutrophil counts with inhaled steroids. Both patients with NRA and those with RA were receiving inhaled steroids in our study. However, unlike patients with RA, not all patients with NRA received maximal doses of inhaled steroids. Thus it is possible that higher doses of inhaled steroids in patients with RA contributed to some extent to airway neutrophilia. Environmental toxicants frequently induce cytokines/chemokines that can elicit low-level neutrophilic inflammation.[@bib40] There could be a cumulative effect during aging. The T~H~17 immune response induces neutrophilic inflammation in animal models.[@bib16] Our assay did not detect IL-17, likely because of the low sensitivity of the assay. However, the assay detected increased levels of multiple proneutrophilic biomolecules, including SAA, NAP2, thrombospondin 1, IL-6, IL-8, C3, CCL3, CCL20, epidermal growth factor, and receptor for advanced glycosylation end products. All except the last 3 significantly correlated with BAL fluid neutrophil counts. SAA induces granulocyte colony-stimulating factor and stimulates neutrophil generation.[@bib41] It also induces T~H~17.[@bib42] IL-6 is an inducer of T~H~17[@bib43] and a marker of systemic inflammation.[@bib44] NAP2, IL-8, C3, and CCL3 directly induce neutrophilic inflammation.[@bib45], [@bib46], [@bib47], [@bib48] C3 also induces IL-1, IL-8, and other cytokines/chemokines, which could indirectly affect neutrophilic inflammation.[@bib48] Some of our findings on biomolecules are in agreement with those of many previous studies. Similar to our finding, IL-1β and IL-6 discriminated severe from moderate asthma in a SARP study.[@bib25] IL-8 levels have previously been reported to be increased in sputum[@bib49], [@bib50] and BAL fluid[@bib51] from patients with RA and neutrophilic asthma.

Although the existence of neutrophilic asthma in the absence of infection has been known for many years, its mechanism is poorly understood. Our study identified a unique subgroup of infection-negative patients with neutrophilic RA, which was selectively associated with increased markers of inflammation in serum. These markers included IL-1β, IL-6, IL-8, CXCL1, and CCL3. The concomitant increase in C-reactive protein levels in the same patients suggested a systemic inflammatory process akin to what has been observed in patients with atherosclerotic cardiovascular[@bib52] and autoinflammatory[@bib53] diseases. Remarkably, this subgroup of patients also had increases in 2 additional cardiovascular risk factors: GDF-15[@bib54] and soluble ST2 (IL-33 receptor).[@bib52] We recognize that the latter is a nonspecific biomarker of systemic inflammation. Four (11%) of 36 (11%) infection-negative patients with neutrophilic RA and 5 (21%) of 24 infection-positive patients with neutrophilic RA had a history of cardiovascular disease. Therefore the frequency of existing cardiovascular disease did not explain the systemic (serum) increase in levels of these inflammatory cytokines. We also did not find any correlation of these inflammatory cytokines with other common comorbidities: diabetes and autoimmune disorders.

There are multiple known mechanisms for induction of IL-1, IL-6, IL-8, CXCL1, and CCL3. This constellation of inflammatory cytokines also constitutes the senescence-associated secretory product.[@bib55] Senescence is a biological process that defends against DNA damage--induced carcinogenesis but, by producing multiple cytokines, contributes to systemic inflammation.[@bib56] Recently, GDF-15 has been shown to induce cellular senescence.[@bib57] The correlation of neutrophilic asthma with age also raises the possibility that senescence contributed to the increased proneutrophilic cytokine profile in the serum. Additional studies will be needed to establish the relationship between cellular senescence and predisposition to neutrophilic RA.

It should be noted that 37% of infection-positive patients with RA did not have neutrophilia in BAL fluid, which further underscores the notion that this was a subclinical infection. Nearly half of them had increased eosinophil counts in BAL fluid, suggesting type 2 immunodominant asthma. Type 2 cytokines inhibit IL-8 and other proneutrophilic cytokines,[@bib58] which could explain the lack of neutrophilia. However, the absence of neutrophilia in noneosinophilic infection-positive patients with RA suggests a defective immune response or perhaps an active immune evasion by the microbial organism.

Of the 14 serum biomolecules that were different among the study groups, only 5 biomolecules overlapped with those from the BAL fluid. However, the pattern of change was different from that in BAL fluid. Four of these biomolecules showed reduced expression in patients with NRA but not in those with RA when compared with expression in healthy control subjects. The reason for this reduced expression in patients with NRA but not those with RA is not clear. Ficolin 3 is the only biomolecule in the serum that distinguished RA from NRA. Ficolin 3 is a recognition molecule of the lectin pathway of the complement system. Its deficiency is associated with increased infection.[@bib59]

If subclinical infection is one of the mechanisms of RA in a subgroup of patients, its importance can be tested through targeted and bacterial strain--specific antibiotic therapy. We are aware that antibiotic therapy of patients with RA produced mixed results in the past.[@bib60], [@bib61] The failure of antibiotic therapy in some studies could be due to inappropriate selection of study patients (eg, inclusion of patients who did not have any infection) and use of an inappropriate antibiotic.[@bib3] Note that we detected both gram-positive and gram-negative bacteria, as well as viruses, in patients with RA. The results underscore the importance of the selection of an appropriate antibiotic (targeting gram-positive vs gram-negative bacteria) and its application to a properly identified target patient population. If low-level systemic inflammation is indeed the cause of airway neutrophilia in infection-negative patients with RA, this hypothesis can be tested by using therapeutic agents targeting molecules, such as IL-1, IL-6, and IL-8. Some of these therapeutic agents are already in use in patients with rheumatologic conditions.

The number of CD117^+^ cells representing mostly mast cells was reduced in patients with RA. Reduced numbers of tryptase-positive cells representing mast cells in patients with severe asthma was previously reported in a SARP study.[@bib62] This was thought to be due to the loss of tryptase as a consequence of mast cell degranulation. However, unlike tryptase, CD117 is a cell-surface marker and not a granular protein and is not expected to be affected by mast cell degranulation. It is possible that the reduced CD117^+^ cell number is a consequence of the underlying disease process.Clinical implicationsThis study identifies airway neutrophils and proneutrophilic biomolecules as significant contributors to RA. A subgroup of neutrophilic asthma was associated with a subclinical infection. This group is likely to benefit from specific antimicrobial therapy. Neutrophilic asthma without a subclinical infection showed signs of systemic inflammation. Therapies targeting proneutrophilic biomolecules, autoinflammation, or both are likely to control asthma in this subgroup.

Appendix {#appsec1}
========

Fig E1Study design and overview of the results. **A,** Schematic presentation of study design. **B,** Inserted table summarizes the number of biomolecules studied, not detected, changed, and unchanged in BAL fluid and serum from the study subjects. **C,** Number of biomolecules in BAL fluid that were significantly (*P* \< .05) different among study populations.Fig E2Fold increase in biomolecule level in patients with RA compared with those with NRA (**A** and **B**). Patients with RA were subgrouped as having infection (infection positive, *black bars*) or no infection (infection negative, *gray bars*). Results in Fig E2, *A*, were separated from results in Fig E2, *B*, because of the higher level of increase (see labels on *x-axis*).Table E1List of biomoleculesAnalytesUnitsMyriad RBM LDDMyriad RBM LLOQAdiponectinμg/mL0.0000860.00030Agouti-related protein (AgRP)pg/mL2423Aldose reductaseng/mL0.410.67Alpha-1-antichymotrypsin (AACT)μg/mL0.701.4Alpha-1-antitrypsin (AAT)mg/mL0.0000000380.000000082Alpha-1-microglobulin (A1Micro)μg/mL0.0000140.000025Alpha-2-macroglobulin (A2Macro)mg/mL0.0000980.000087Alpha-fetoprotein (AFP)ng/mL0.0140.11Amphiregulin (AR)pg/mL131199Angiogeninng/mL0.0160.0081Angiopoietin 2 (ANG-2)ng/mL0.0480.048Angiotensin-converting enzyme (ACE)ng/mL0.0190.035Angiotensinogenng/mL0.0510.092Apolipoprotein(a) (Lp\[a\])μg/mL0.000200.00091Apolipoprotein A-I (Apo A-I)mg/mL0.0000000160.00000006Apolipoprotein A-II (Apo A-II)ng/mL0.0000110.000014Apolipoprotein A-IV (Apo A-IV)μg/mL0.0750.16Apolipoprotein B (Apo B)μg/mL0.000440.0021Apolipoprotein C-I (Apo C-I)ng/mL0.00000620.000022Apolipoprotein C-III (Apo C-III)μg/mL0.00000240.000011Apolipoprotein D (Apo D)μg/mL0.0200.037Apolipoprotein E (Apo E)μg/mL0.000890.0024Apolipoprotein H (Apo H)μg/mL0.0000150.000062AXL receptor tyrosine kinase (AXL)ng/mL0.00580.010B cell-activating factor (BAFF)pg/mL1.53.7B-lymphocyte chemoattractant (BLC)pg/mL9.812Beta-2-microglobulin (B2M)μg/mL0.0000450.000051Betacellulin (BTC)pg/mL1927Brain-derived neurotrophic factor (BDNF)ng/mL0.00460.00726 Conserved cysteine containing CC-chemokinepg/mL8.215C-peptideng/mL0.00410.0030C-reactive protein (CRP)μg/mL0.00000340.0000078Calbindinng/mL0.530.90Cancer antigen 125 (CA-125)U/mL0.450.76Cancer antigen 15-3 (CA-15-3)U/mL0.0550.090Cancer antigen 19-9 (CA-19-9)U/mL2.11.4Cancer antigen 72-4 (CA 72-4)U/mL6.54.0Carcinoembryonic antigen (CEA)ng/mL0.0280.037Cathepsin Dng/mL0.230.18CD5 antigen-like (CD5L)ng/mL0.00560.0081CD40 antigen (CD40)ng/mL0.00360.0031CD40 ligand (CD40L)ng/mL0.00370.0033Cellular fibronectin (cFib)μg/mL0.00890.042Chemokine CC4 (HCC-4)ng/mL0.00660.0095Chromogranin-A (CgA)ng/mL5.02.6Ciliary neurotrophic factor (CNTF)pg/mL4.519Clusterin (CLU)μg/mL0.00130.0024Collagen IVng/mL1.21.9Complement C3 (C3)mg/mL0.0000000160.0000001Complement factor H--related protein 1 (CFHR1)μg/mL0.000760.0011Cortisol (Cortisol)ng/mL1.22.0Creatine kinase-MB (CK-MB)ng/mL0.0350.070Cystatin-Cng/mL0.0110.0075E-selectinng/mL0.0330.041EN-RAGEng/mL0.00360.0076Endoglinng/mL0.00230.0041Endostatinng/mL0.0140.054Eotaxin-1pg/mL1.929Eotaxin-2pg/mL4.77.6Eotaxin-3pg/mL1631Epidermal growth factor (EGF)pg/mL0.785.8Epidermal growth factor receptor (EGFR)ng/mL0.0310.058Epiregulin (EPR)pg/mL3.714Epithelial cell adhesion molecule (EpCam)pg/mL1680Epithelial-derived neutrophil-activating protein 78 (ENA-78)ng/mL0.00300.017Ezrinng/mL2.53.6Factor VIIng/mL1.20.77Fas ligand (FasL)pg/mL2.65.3FASLG receptor (FAS)ng/mL0.471.2Fatty acid--binding protein, adipocyte (FABP, adipocyte)ng/mL0.0230.049Fatty acid--binding protein, heart (FABP, heart)ng/mL1.03.0Fatty acid--binding protein, liver (FABP, liver)ng/mL2.84.8Ferritin (FRTN)ng/mL0.0130.021Fetuin-Aμg/mL0.000340.00062Fibrinogenmg/mL0.000000220.00000024Fibroblast growth factor 4 (FGF-4)pg/mL12387Fibroblast growth factor basic (FGF-basic)pg/mL5.96.9Fibulin-1C (Fib-1C)μg/mL0.000150.00015Follicle-stimulating hormone (FSH)mIU/mL0.110.13Galectin-3ng/mL0.0710.074Gelsolinμg/mL0.000340.00072Glucagonpg/mL3164Glucagon-like peptide 1, active (GLP-1 active)pg/mL1.42.6Glucagon-like peptide 1, total (GLP-1 total)pg/mL0.891.1Glucose-6-phosphate isomerase (G6PI)ng/mL0.0620.12Glutathione S-transferase α (GST-α)ng/mL0.290.59Glutathione S-transferase Mu 1 (GST-M1)ng/mL0.581.3Granulocyte colony-stimulating factor (G-CSF)pg/mL0.731.1Granulocyte-macrophage colony-stimulating factor (GM-CSF)pg/mL3.218Growth hormone (GH)ng/mL0.00540.030Growth-regulated α protein (GRO-α)pg/mL0.360.94Haptoglobinmg/mL0.000000120.00000032HE4pmol/L1614Heat shock protein 60 (HSP-60)ng/mL5.37.4Heparin-binding EGF-like growth factor (HB-EGF)pg/mL9.243Hepatocyte growth factor (HGF)ng/mL0.330.20Hepatocyte growth factor receptor (HGF receptor)ng/mL0.0550.079Hepsinpg/mL1514Human chorionic gonadotropin β (hCG)mIU/mL0.240.45Human epidermal growth factor receptor 2 (HER-2)ng/mL0.00290.0060IgAmg/mL0.0000000350.00000028IgEμ/mL0.433.6IgMmg/mL0.000000360.00000047Insulinmg/mL0.00350.043Insulin-like growth factor-binding protein 1 (IGFBP-1)ng/mL0.110.19Insulin-like growth factor-binding protein 2 (IGFBP-2)ng/mL0.570.48Insulin-like growth factor-binding protein 3 (IGFBP-3)ng/mL1.23.2Insulin-like growth factor binding protein 4 (IGFBP4)ng/mL0.190.30Insulin-like growth factor binding protein 5 (IGFBP5)ng/mL1.31.9Insulin-like growth factor binding protein 6 (IGFBP6)ng/mL0.650.77Intercellular adhesion molecule 1 (ICAM-1)ng/mL0.350.26IFN-γpg/mL0.490.30IFN-γ induced protein 10 (IP-10)pg/mL2.925Interferon-inducible T-cell α chemoattractant (ITAC)pg/mL4.04.2IL-1αng/mL0.000300.00040IL-1βpg/mL0.300.57IL-1 receptor antagonist (IL-1ra)pg/mL9.919IL-2pg/mL1.01.7IL-2 receptor α (IL-2 receptor α)pg/mL2518IL-3ng/mL0.00110.0032IL-4pg/mL4.45.9IL-5pg/mL1.02.6IL-6pg/mL0.842.2IL-6 receptor (IL-6r)ng/mL0.00270.0054IL-6 receptor subunit β (IL-6Rβ)ng/mL0.0230.049IL-7pg/mL2.11.8IL-8pg/mL0.630.79IL-10pg/mL1.11.4IL-12 subunit p40 (IL-12p40)ng/mL0.0160.055IL-12 subunit p70 (IL-12p70)pg/mL5.99.7IL-13pg/mL0.631.2IL-15ng/mL0.120.079IL-16pg/mL4.317IL-17pg/mL1.20.99IL-18pg/mL3.78.3IL-23ng/mL0.120.080Kallikrein 5ng/mL0.0450.14Kallikrein-7 (KLK-7)pg/mL9067Kidney injury molecule-1 (KIM-1)ng/mL0.00710.0030Lactoylglutathione lyase (LGL)ng/mL0.0390.18Latency-associated peptide of transforming growth factor β1 (LAP TGF-β1)ng/mL0.00920.015Lectin-like oxidized LDL receptor 1 (LOX-1)ng/mL0.160.18Leptinng/mL0.0110.027Luteinizing hormone (LH)mIU/mL0.0420.15Macrophage colony-stimulating factor 1 (M-CSF)ng/mL0.0350.053Macrophage-derived chemokine (MDC)pg/mL1.23.7Macrophage inflammatory protein-1 α (MIP1α)pg/mL8.28.4Macrophage inflammatory protein-1 β (MIP1β)pg/mL4.06.2Macrophage inflammatory protein-3 γ (MIP3α)pg/mL2.56.0Macrophage inflammatory protein 3β (MIP3β)pg/mL3.27.8Macrophage migration inhibitory factor (MIF)ng/mL0.00150.0020Macrophage-stimulating protein (MSP)ng/mL0.0370.051Malondialdehyde-modified low-density lipoprotein (MDA-LDL)ng/mL2549Maspinpg/mL466353Matrix metalloproteinase-1 (MMP-1)ng/mL0.120.18Matrix metalloproteinase-2 (MMP-2)ng/mL1.30.87Matrix metalloproteinase-3 (MMP-3)ng/mL0.00660.012Matrix metalloproteinase-7 (MMP-7)ng/mL0.0170.0088Matrix metalloproteinase-9 (MMP-9)ng/mL5.07.9Matrix metalloproteinase-9, total (MMP-9, total)ng/mL0.260.34Matrix metalloproteinase-10 (MMP-10)ng/mL0.00270.0054Mesothelin (MSLN)nmol/L0.320.31MHC class I chain--related protein A (MICA)pg/mL9.215Monocyte chemotactic protein 1 (MCP-1)pg/mL4.69.0Monocyte chemotactic protein 2 (MCP-2)pg/mL1.11.3Monocyte chemotactic protein 3 (MCP-3)pg/mL0.451.9Monocyte chemotactic protein 4 (MCP-4)pg/mL13189Monokine induced by IFN-γ (MIG)pg/mL1022Myeloid progenitor inhibitory factor 1 (MPIF-1)ng/mL0.00520.028Myeloperoxidase (MPO)ng/mL3.23.7Myoglobinng/mL0.0110.040N-terminal prohormone of brain natriuretic peptide (NT proBNP)pg/mL1115Nerve growth factor β (NGF-β)ng/mL0.00990.016Neuron-specific enolase (NSE)ng/mL0.0300.035Neuronal cell adhesion molecule (Nr-CAM)ng/mL0.0440.040Neuropilin-1ng/mL0.000770.0017Neutrophil gelatinase-associated lipocalin (NGAL)ng/mL0.0130.058Osteopontinng/mL0.300.62Osteoprotegerin (OPG)pmol/L0.0750.17Pancreatic polypeptide (PPP)pg/mL0.110.96Pepsinogen I (PGI)ng/mL0.0290.029Peptide YY (PYY)pg/mL3126Phosphoserine aminotransferase (PSAT)ng/mL0.0670.12Placenta growth factor (PLGF)pg/mL3.711Plasminogen activator inhibitor 1 (PAI-1)ng/mL0.00790.016Platelet-derived growth factor BB (PDGF-BB)pg/mL31144Progesteroneng/mL0.450.65Proinsulin, intactpmol/L1.40.73Proinsulin, totalpmol/L7.96.7Prolactin (PRL)ng/mL0.0130.017Prostasinng/mL0.280.33Prostate-specific antigen, free (PSA-f)ng/mL0.000530.0027Protein S100-A4 (S100-A4)ng/mL1.01.9Pulmonary and activation-regulated chemokine (PARC)ng/mL1.21.2Receptor for advanced glycosylation end products (RAGE)ng/mL0.0340.069Receptor tyrosine-protein kinase erbB-3 (ErbB3)ng/mL0.00860.0065Resistinng/mL0.00120.0052S100 calcium-binding protein B (S100-B)ng/mL0.0760.099Serotransferrin (transferrin)mg/dL0.00000690.000047Serum amyloid P-component (SAP)μg/mL0.0000110.000014Sex hormone-binding globulin (SHBG)nmol/L0.000380.0010Sortilinng/mL0.0460.044Squamous cell carcinoma antigen-1 (SCCA-1)ng/mL0.0530.22Stem cell factor (SCF)pg/mL1823Stromal cell--derived factor-1 (SDF-1)pg/mL8.713Superoxide dismutase 1, soluble (SOD-1)ng/mL0.0320.024T cell--specific protein RANTES (RANTES)ng/mL0.000180.0010T lymphocyte--secreted protein I-309 (I-309)pg/mL7.011Tamm-Horsfall urinary glycoprotein (THP)μg/mL0.0000450.00011Tenascin-C (TN-C)ng/mL5.79.7Testosterone, Totalng/mL0.0610.10Tetranectinμg/mL0.000930.0025Thrombomodulin (TM)ng/mL0.0170.049Thrombospondin 1ng/mL0.120.35Thyroglobulin (TG)ng/mL1.82.8Thyroid-stimulating hormone (TSH)uIU/mL0.00360.0077Thyroxine-binding globulin (TBG)μg/mL0.0000190.000035Tissue inhibitor of metalloproteinases 1 (TIMP-1)ng/mL0.0100.016Tissue-type plasminogen activator (tPA)ng/mL0.00750.089TNF-related apoptosis-inducing ligand receptor 3 (TRAIL-R3)ng/mL0.0340.19TGF-αpg/mL4.617TGF-β3pg/mL4.221Transthyretin (TTR)mg/dL0.000000950.000004Trefoil factor 3 (TFF3)μg/mL0.000050.00010TNF-αpg/mL2.94.5TNF-βpg/mL2.31.9TNF receptor I (TNF RI)pg/mL5.97.6TNF receptor 2 (TNFR2)ng/mL0.00110.0057Tyrosine kinase with immunoglobulin and EGF homology domains 2 (TIE-2)ng/mL0.0210.036Urokinase-type plasminogen activator (uPA)pg/mL8.123Urokinase-type plasminogen activator receptor (uPAR)ng/mL0.0340.059Vascular cell adhesion molecule 1 (VCAM-1)ng/mL0.00900.057Vascular endothelial growth factor (VEGF)pg/mL126.8Vascular endothelial growth factor B (VEGF-B)ng/mL2.72.3Vascular endothelial growth factor C (VEGF-C)ng/mL0.191.1Vascular endothelial growth factor D (VEGF-D)pg/mL100100Vascular endothelial growth factor receptor 1 (VEGFR-1)pg/mL2991Vascular endothelial growth factor receptor 2 (VEGFR-2)ng/mL0.00740.12Vascular endothelial growth factor receptor 3 (VEGFR-3)ng/mL0.261.1Vitamin D--binding protein (VDBP)μg/mL0.000020.000028Vitamin K--dependent protein S (VKDPS)μg/mL0.0000210.000022Vitronectinμg/mL0.0130.029von Willebrand factor (vWF)μg/mL0.00160.0034YKL-40ng/mL0.00400.0073[^9][^10]Table E2Predominant cellular sources of biomoleculesBiomoleculeCellular sourceBiomoleculeCellular sourceInnate immune cell--derived biomoleculesMixed cell--derived biomolecules1. C3M, DC1. IL-1βMost cell types2. CCL3 (MIP1β)M2. IL-6M, DC, Ep3. CXCL7 (NAP2)P, M3. IL-8Ep, M, En, F, SM4. Ficolin-3M4. Lipocalin 2N, Ep5. MMP9, totalN5. MMP7N, Ep6. PAIM, Ma, EpAirway tissue--derived biomolecules7. SAAM, Ep 1. Thrombospondin 1F[^11]Table E3Correlation of serum biomolecule levels with inflammatory cell countsVariablesCorrelation with BAL fluid neutrophil counts *(r)P* valueCorrelation with BAL fluid eosinophil counts *(r)P* valueCorrelation with BAL fluid lymphocyte counts *(r)P* valueSerum biomolecule levels associated with neutrophil counts 1. GDF-150.44.003−0.1NS−0.18NS *2. Human Epididymis protein 4*0.43.0040.29.05−0.05NS 3. MMP70.35.02−0.06NS−0.25NS 4. Tetranectin−0.35.020.02NS0.06NS 5. von Willebrand factor0.34.020.08NS0.03NS[^12]Table E4Chest CT findings in infection-positive patients with RAIdentifierDescription of chest CT findings001RBronchial wall thickening003RBronchiolitis, consistent with aspiration, ground glass, consistent with asthma, consistent with reflux, esophageal thickening004RBronchial wall thickening, consistent with asthma, bronchiectasis, infiltrates, hiatal hernia, esophageal thickening, consistent with reflux, air trapping005RBronchial wall thickening, consistent with aspiration, consistent with asthma, tracheobronchomalacia, pulmonary hypertension, consistent with reflux, esophageal thickening, hiatal hernia006RBronchial wall thickening, consistent with aspiration, consistent with asthma, dysmotility, consistent with reflux008RTracheobronchomalacia, bronchial wall thickening, consistent with asthma, consistent with aspiration, dysmotility, consistent with reflux011RBronchial wall thickening, bronchiectasis, air trapping, hiatal hernia, dysmotility015RHiatal hernia, esophageal thickening, bronchial wall thickening, air trapping, consistent with reflux012RBronchiectasis, bronchial wall thickening, consistent with asthma, scarring, hiatal hernia, dysmotility020RBronchial wall thickening, ground glass, esophageal thickening, hiatal hernia, dysmotility, consistent with reflux021RBronchial wall thickening, consistent with asthma, consistent with aspiration, hiatal hernia, consistent with reflux, esophageal thickening030RBronchial wall thickening, hiatal hernia, esophageal thickening033RHiatal hernia, bronchiectasis, consistent with aspiration, bronchial wall thickening, air trapping035RBronchial wall thickening, consistent with asthma, esophageal thickening, dysmotility, consistent with reflux, air trapping, tracheobronchomalacia018RAir trapping, bronchial wall thickening, consolidation, hiatal hernia, esophageal thickening, bronchiectasis, consistent with reflux047RTracheobronchomalacia, consistent with reflux, consistent with aspiration, consistent with asthma, bronchial wall thickening, air trapping, esophageal thickening048RBronchial wall thickening, atelectasis049RHiatal hernia, bronchial wall thickening, scarring, granuloma, air trapping, tracheobronchomalacia053RBronchial wall thickening, atelectasis, air trapping, consistent with asthma055RBronchial wall thickening, scarring, ground glass, consistent with reflux, hiatal hernia, consistent with asthma, consistent with aspiration061RBronchial wall thickening, atelectasis, scarring, air trapping, consistent with asthma062REsophageal thickening, bronchial wall thickening, atelectasis, scarring, air trapping, consistent with reflux, dysmotility, consistent with aspiration063REsophageal thickening, bronchial wall thickening, air trapping, consistent with asthma068RBronchial wall thickening, atelectasis, scarring, air trapping, tracheobronchomalacia, dysmotilityTable E5List of medicationsPatient IDAsthma medications (ICS, LABA, oral steroid and SABA)Oral steroidMedication by pharmacologic classOthers002NRAAdvair 250/50 bid, Xopenex prnNo003NRASymbicort 160/4.5 2 puffs bid, albuterol prnNo004NRAProventil prn, Advair HFA 230/12 bidNo005NRAAlvesco 80 μg qd, Albuterol prnNo007NRAAlvesco 80 μg 2 puffs qd, Albuterol MDI prnNo008NRAXopenex prn, Advair 100/50No009NRAAdvair 250/50 bidNo010NRAFlovent 220 bid, albuterol prnNo011NRADulera 100/5 bid, albuterol prnNo012NRAQVAR 80 bid, albuterol prnNo013NRAFlovent 44 2 puffs bidNo014NRAAlvesco 160; Xopenex prnNo015NRAQVAR 80 2 puffs/dNo016NRAQVAR 80 2 puffs/bid; albuterol prnNo017NRAFlovent 220 bidNo018NRAFlovent 220 bid, albuterol prnNo022NRADulera 100/5 bidNo024NRAQVAR 2 puffs bidNo026NRAAdvair 100/50 bidNo027NRAAlvesco 160 2 puffs/d; Xopenex prnNo028NRAFlovent 110 2 puffs/d, albuterol prnNo029NRAAdvair 250/50 bid; ProAir prnNo030NRAAdvair 250/50 bid; albuterol once/wkNo036NRAQVAR 80 2 puffs/d; albuterol prnNo039NRAPulmicort 180 μg/d, ProAir prnNo040NRADulera 100/50 2 puffs bid; Ventolin prnNo042NRAQVAR 80 2 puffs/d; Proventil prnNo044NRAAdvair 100/50 bidNo046NRAAdvair 100/50, Proventil prnNo049NRAQVAR 80 bidNo001RAdvair 500/50 bid, monthly prednisone tapers, QVAR 160 μg bidYes002RSpiriva 18 μg/d, Symbicort 160/4.5 2× bid, albuterol prn, Singulair 10 mg/d, QVAR 80 μg 4× bidNoLAMA, ICS, LTRA003RDulera 200/5.0 2× bid, fluticasone 220 2× bid, Xopenex prnNoICS004RPrednisone 40 mg/d; Symbicort 160 2× bid; Combivent 2 puffs prn; DuoNeb prnYesLAMA005RAdvair HFA 230/21 2 puffs bid; albuterol prn, prednisone, Singulair 10 mg qd, ProventilYesLTRA006RDulera 200 two puffs bid; albuterol neb prn, Acapella deviceNo007R40 mg prednisone daily, Advair 500/50 bid, Singulair 10 mg/dYesLTRA008RSymbicort 160/4.5 2 puffs bid; QVAR 4 puffs bid; Proventil prnNoICS009RAdvair 500/50 bid, QVAR 80 2× bid, Singulair 10 mgNoICS, LTRA010RAdvair 250/50 bid; Singulair 10 mg/d; ProAir prnNoLTRA011RAdvair 250/50 bid, Ventolin 2× bidNo012RAdvair 500/50 bid, Singulair 10 mg qd, Spiriva once daily, Xopenex neb prnNoLAMA, LTRA013RAdvair 500/50 bid, Flovent 110 twice bid, Singulair 10 mg/d, Ventolin prnNoICS, LTRA015RAdvair HFA 230/21 2 puffs bid, prednisone 60 mg qd, Ventolin prn, Combivent 18-103 prnYesLAMA016RXolair, Symbicort 160/4.5 two puffs bid, Spiriva qd, theophylline 900 mg qd, albuterol neb prnNoLAMA, theophylline, Xolair017RSymbicort 160/4.5 2 puffs bid; Alvesco 160 2 puffs bid; Xopenex prnNoICS018RZyflo CR 1200 mg bid; Advair HFA 230/21 two puffs bidNoZileuton020RPrednisone 60 mg qd; Singulair 10mg qd; Advair 500/50 bidYesLTRA021RAlbuterol HFA prn; Asmanex 220 μg bid; prednisone 15 mg qd; Serevent bid; Zyflo 600 mg qdYesZileuton022RDulera 200/5.0 2 puffs bid, Pulmicort 180 μg 2 puffs bid, Singulair 10 mg qd, Ventolin prnNoICS, LTRA023RAdvair 500/50 bid, Ventolin 2 puffs every 4 h, DuoNeb prnNo024RTheophylline 300 mg 3×/d; albuterol neb prn; Ventolin HFA prn; Symbicort 160-4.5 μg 2 puffs bid; Spiriva HandiHaler 18 μg qd; Alvesco 160 μg 2 puffs bid; Accolate 20 mg bid; prednisone 2 mg/dYesLAMA, LTRA, Theophylline025RAdvair 500/50 bid, ProAir HFA prnNo026RSingulair 10 mg, Daliresp 500 mg, Advair 500/50 bid; Alvesco 160 bid; prednisone taper prn on monthly basis, Proventil MDI prn; albuterol neb prn; XolairYesLTRA, roflumilast, Xolair028RPrednisone 20 mg bid; Symbicort 160/4.5 two puffs bid and QVAR 80 μg 2-4 puffs BID; albuterol HFA or neb PRNYes029R20 mg prednisone; theophylline 300 mg 3×/d; Spiriva neb prn every 2-4 h; albuterol every 2-4 h; Zyflo 600 mg bid; Advair 230/21 two puffs bid; Xolair 150 mg every 2 moYesLAMA, LTRA, theophylline, Xolair, zileuton030RProAir HFA; prednisone taper ongoing; Dulera 200-5 2 puffs bidYes031R30 mg Prednisone; albuterol/ipratropium neb bid; Dulera 200/5 two puffs bid; Albuterol prn; XolairYesLAMA, Xolair032RAdvair 230/21 two puffs BIDNo033RSymbicort 160/4.5 two puffs BID; DuoNebNo034RAdvair 500/50 BID; ProAir 2 puffs prn; QVAR 80 three puffs bidNoICS035RSpiriva 18 μg/d; Flovent HFA 220 μg 2 puffs bid; Ventolin and Xopenex prnNoLAMA036RAdvair 500/50 with QVAR 80 two puffs bidNo037R10 mg Prednisone/d; Advair 500/50 bid; Pro-Air prnYes038RAlbuterol HFA prn; Proventil HFA 108 prn; Pulmicort 180 2 puffs bid; QVAR 2 puffs bidNoICS039RSymbicort 160/4.5 two puffs bid; QVAR 2 puffs bid; ProAir and albuterol neb prn; Zyrtec 10 mgNoICS041RAlbuterol neb prn; Albuterol HFA prn; Dulera AERO 2 puffs bid; Prednisone 10 mg every other dayYes042R5 mg/d Prednisone, Advair 500/50 bid; Spiriva 18 μg/d; albuterol neb daily prnYesLAMA043RSymbicort 160 two puffs bid; Flovent 110 two puffs once/day; Xopenex neb BID; Spiriva qdNoICS, LAMA046RSymbicort 160/4.5 two puffs bid; prednisone 20 mg every other dayYes047RIpratropium-albuterol for neb prn; Advair HFA AERONoLAMA048RAlbuterol prn; Dulera 200-5 two puffs bidNo049RAdvair 500/50 bid; Prednisone 10 mg 3×/wk; albuterol prn; Xolair; ProAir HFA 2 puffs every 4-6 hYesXolair050RDulera 100/5 two puffs bid; QVAR 80 two puffs bid; Zyflo 1200 mg bid; prednisone 20 mg qd; nasal saline washesYes051RAdvair 500/50 BIDNo052RDulera 200/5 2 puffs bid; Ventolin prn; Zyrtec 10-20 mg; Nasonex prn; Albuterol neb prnNo053RAdvair HFA 230 two puffs bid; fluticasone nasal spray, theophylline 300 bid, albuterol prnNo054RSymbicort 160/4.5 two puffs bid; QVAR 80 μg 3 puffs bid; montelukast 10 mg; Allegra 180 mg; Fluticasone 50 μg; Ventolin prn; NSWNo055RAlbuterol nebs/MDI prn; Brovana 15 μg neb bid; budesonide 1000 mg neb bid; Pulmicort; Omeprazole 40 mg bid; ranitidineNo056RAlbuterol neb tid; Symbicort 160/4.5 two puffs bid, Singulair 10 mg; saline nasal rinse with budesonide 0.5 mg twice a dayNo057RAlbuterol nebulizer treatment every 4 h; Dulera 200/5 two puffs bid; Asmanex to 2 puffs bid, ProAir prn; Spiriva daily; Flonase; SingulairNo058RDulera 200-5MCG/ACT 2 puffs bis; ProAir inhaler prn; Singulair 10 mg; Zyrtec; Zetonna; QVAR 2 puffs bid, Nexium 40 mgNoXolair, Zetonna059RPrednisone 10 mg/d, ProAir HFA prn; Dulera 200/5 2p bid; DuoNeb prnYes060RXopenex and Atrovent nebulizers prn; Symbicort 160 two puffs bidNo061RSingulair; albuterol nebulizer prn; Advair 500/50 bid, Cetirizine prn, FlonaseNo062RAdvair 500 μg bid, albuterol MDI/nebNo063RAlvesco, methylprednisolone 4 mg qd, Prilosec, Qnasl, Spiriva, Symbicort 160, Theophylline 300 mg bid, Ventolin prn, Zyrtec, Nasacort, Patanase nasal solutionYesTheophylline066RPulmicort 180 μg 2 puffs bid, Symbicort 160/4.5 two puffs bid, theophylline, DuoNebNoTheophylline067RQVAR 80 μg 2 puffs twice daily; Symbicort 160/4.5 two puffs twice daily; albuterol nebs prn; Singulair 10 mg/dNoFlonase prn; NSW prnLipitor, Lisinopril068RAlbuterol inhaler/neb prn, Symbicort 160 two puffs bid, QVAR 80 two puffs bid, ZyrtecYes[^13]Table E6Correlations among clinical and laboratory variablesVariablesCorrelation FEV~1~ (% *\[r\]*)*P* valueCorrelation with FVC (% *\[r\]*)*P* valueCorrelation with reversibility *(r)P* valueInflammatory cells PMN, BAL fluid−0.16NS−0.32.010.15NS Eosinophils, BAL fluid−0.23NS−0.20NS0.15NS Lymphocytes, BAL fluid0.03NS0.05NS−0.15NS Eosinophils, blood0.02NS0.04NS0.06NSBAL biomolecules Myoglobin−0.24.05−0.27.030.12NS Prostasin0.27.030.15NS−0.27.04Table E7GO (biological process) pathway analysisAnnotation (pathway/process)XD scoreFisher *q* valueGene set sizePathway sizeOverlap sizeGO:0090023∼positive regulation of neutrophil chemotaxis0.59764090.588401151GO:0044344∼cellular response to fibroblast growth factor stimulus0.59764090.588401151GO:0050930∼induction of positive chemotaxis0.52705270.588401171GO:0048566∼embryonic digestive tract development0.44764090.588401201GO:0031623∼receptor internalization0.31906950.588401281GO:0071347∼cellular response to IL-10.29764090.588401301
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[^1]: *BM*, Basement membrane thickness; *BMI*, body mass index; *HPF*, high-powered field; *WBC*, white blood cells.

[^2]: *EGF*, Epidermal growth factor; *ICAM*, intercellular adhesion molecule; *MIF*, macrophage migration inhibitory factor; *MIG*, monokine induced by IFN-γ; *MIP*, macrophage inflammatory protein; *NS*, not significant; *PAI-I*, plasminogen activator inhibitor 1; *RAGE*, receptor for advanced glycosylation end products; *SP-D*, surfactant protein D; *TIMP-1*, tissue inhibitor of metalloproteinases 1; *TNFSF12 and 13*, tumor necrosis factor superfamily members 12 and 13; *VEGF*, vascular endothelial growth factor; *vWF*, von Willebrand factor.

[^3]: Steroid sensitive.

[^4]: *EGF*, Epidermal growth factor; *MIP*, macrophage inflammatory protein; *NS*, not significant; *RAGE*, receptor for advanced glycosylation end products; *TIMP-1*, tissue inhibitor of metalloproteinases 1.

[^5]: Italicized biomolecules are also changed in the serum.

[^6]: *EGF*, Epidermal growth factor; *MIP*, macrophage inflammatory protein; *PAI*, plasminogen activator inhibitor; *RAGE*, receptor for advanced glycosylation end products; *TIMP-1*, tissue inhibitor of metalloproteinases 1.

[^7]: Italicized variables were also altered in BAL fluid samples.

[^8]: *NS*, Not significant; *PARC*, pulmonary and activation-regulated chemokine.

[^9]: Least detectable dose *(LDD)* was determined as the mean + 3 SDs of 20 blank readings. Results less than the LDD will be more variable than results greater than the LDD. Lower limit of quantitation *(LLOQ)* was the lowest concentration of an analyte in a sample that can be reliably detected and at which the total error meets the laboratory\'s requirements for accuracy. Myriad RBM\'s requirement for accuracy is the concentration of an analyte at which the coefficient of variation of replicate standard samples is 30%.

[^10]: *MIP*, Macrophage inflammatory protein; *ND*, not detected.

[^11]: *DC*, Dendritic cell; *En*, endothelial cell; *Ep*, epithelial cell; *F*, fibroblast; *M*, macrophage/monocyte; *Ma*, mast cell; *MIP*, macrophage inflammatory protein; *N*, neutrophil; *P*, platelet; *PAI*, plasminogen activator inhibitor; *SM*, smooth muscle.

[^12]: *NS*, Not significant.

[^13]: *bid*, Twice daily; *HFA*, hydrofluoroalkane; *LABA*, long-acting β-agonist; *LAMA*, long-acting muscarinic antagonist; *LTRA*, leukotriene receptor antagonist; *MDI*, metered-dose inhaler; *prn*, as necessary; *qd*, one daily; *tid*, 3 times daily.
